Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 75,827	$ 40,994	$ 191,282	$ 110,012
Product sales, net
Disaggregation of Revenue [Line Items]
Total revenues	75,213	39,141	189,647	90,442
Product sales, net | ORLADEYO
Disaggregation of Revenue [Line Items]
Total revenues	65,395	36,711	179,492	76,023
Product sales, net | RAPIVAB
Disaggregation of Revenue [Line Items]
Total revenues	6,953	2,430	7,290	7,165
Product sales, net | Peramivir
Disaggregation of Revenue [Line Items]
Total revenues	2,865	0	2,865	7,254
Royalty revenue
Disaggregation of Revenue [Line Items]
Total revenues	600	322	1,487	(447)
Milestone revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	15,000
Collaborative and other research and development
Disaggregation of Revenue [Line Items]
Total revenues	14	1,531	148	5,017
Collaborative and other research and development | U.S. Department of Health and Human Services
Disaggregation of Revenue [Line Items]
Total revenues	$ 14	$ 1,531	$ 148	$ 5,017